Cytotoxic activity of ex-vivo generated IFNα-induced monocyte-derived dendritic cells in brain glioma patients

Cellular Immunology

Volumn 284, Issue 1-2, 2013, Pages 146-153

  Tyrinova, Tamara V ^a   Leplina, Olga Yu ^a   Mishinov, Sergey V ^b   Tikhonova, Marina A ^a   Shevela, Ekaterina Ya ^a   Stupak, Vyacheslav V ^b   Pendyurin, Ivan V ^b   Shilov, Alexander G ^c   Alyamkina, Ekaterina A ^c   Rubtsova, Nadezda V ^c   Bogachev, Sergey S ^c   Ostanin, Alexander A ^a   Chernykh, Elena R ^a  

^a INSTITUTE OF CLINICAL IMMUNOLOGY   (Russian Federation)

^b NOVOSIBIRSK RESEARCH INSTITUTE OF TRAUMATOLOGY AND ORTHOPAEDICS N A YA L TSIVYAN   (Russian Federation)

^c INSTITUTE OF CYTOLOGY AND GENETICS   (Russian Federation)

Author keywords

Cytotoxic activity; Dendritic cells; Double stranded DNA; Glioma patients; IFN ; RIL 2

Indexed keywords

ALPHA INTERFERON; CANCER VACCINE; DOUBLE STRANDED DNA; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; APOPTOSIS; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; EX VIVO STUDY; FEMALE; G2 PHASE CELL CYCLE CHECKPOINT; GLIOBLASTOMA; HEP 2 CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; MONOCYTE; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SURVIVAL RATE;

3-(4,5-DIMETHYLTHIAZOL-2-YL)2,5-DIPHENYL TETRAZOLIUM BROMIDE; 7-AAD; 7-AMINOACTINOMYCIN D; CARBOXYFLUORESCEIN SUCCINIMIDYL ESTER; CFSE; CYTOTOXIC ACTIVITY; DCS; DENDRITIC CELLS; DOUBLE-STRANDED DNA; DOUBLE-STRANDED HUMAN DNA; DSDNA; GLIOMA PATIENTS; IFNΑ; INTERFERON ALPHA; LIPOPOLYSACCHARIDE; LPS; MTT; NATURAL KILLER; NK; RECOMBINANT INTERLEUKIN 2; RIL-2; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TNFΑ; TRAIL; TUMOR NECROSIS FACTOR ALPHA;

ADOLESCENT; ADULT; AGED; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; CELL SURVIVAL; CHILD; CYTOTOXICITY TESTS, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; GLIOMA; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERFERON-ALPHA; KAPLAN-MEIER ESTIMATE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; TNF-RELATED APOPTOSIS-INDUCING LIGAND; YOUNG ADULT;

EID: 84883024045     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.07.013     Document Type: Article

References (47)

1. Austyn J.M. Dendritic cells. Curr. Opin. Hematol. 1998, 5(1):3-15.
2. Steinman R.M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 1991, 9:271-296.
3. Lim J.P., Gleeson P.A. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol. Cell Biol. 2011, 89:836-843.
4. Janjic B.M., Lu G., Pimenov A., Whiteside T.L., Storkus W.J., Vujanovic N.L. Innate direct anticancer effector function of human immature dendritic cells. I. Involvement of an apoptosis-inducing pathway. J. Immunol. 2002, 168:1823-1830.
5. Vanderheyde N., Vandenabeele P., Goldman M., Willems F. Distinct mechanisms are involved in tumoristatic and tumoricidal activities of monocyte-derived dendritic cells. Immunol. Lett. 2004, 91:99-101.
6. Wang M., Shi J., Wan Y., Li J., Yuan Y. A subset of myeloid dendritic cells derived from peripheral blood monocytes represented a predominant subset characterized by their potential tumor-inhibiting activity. In Vitro Cell. Dev. Biol. Anim. 2009, 45(7):398-404.
7. Paquette R., Hsu N., Kiertscher S., Park A.N., Tran L., Roth M.D., Glaspy J.A. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 1998, 64:358-367.
8. + T-cell proliferation: modulation by autocrine IL-10, enhanced T-cell apoptosis and T regulatory type 1 cells. Int. Immunol. 2004, 16:1037-1052.
9. Santini S., Lapenta C., Logozzi M., Parlatoa S., Spadaa M., Di Pucchioa T., et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cells development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 2000, 191:1777-1788.
10. Santini S., Pucchini T., Lapenta C., Parlatoa S., Logozzi M., Belardelli F. A new type 1 IFN-mediated pathway for the rapid differentiation of monocytes into highly active dendritic cells. Stem Cells 2003, 21:357-362.
11. + T cells against exogenous viral antigens. Eur. J. Immunol. 2006, 36:2046-2060.
12. Leplina O.Yu., Tyrinova T.V., Stupak V.V., Mishinov S.V., Pendyurin I.V., Ostanin A.A., et al. IFN-α-indused dendritic cell effector functions in healthy donors and malignant brain glioma patients. Russ. J. Immunol. 2011, 5(14):332-343.
13. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide vs. radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009, 10:459-466.
14. Jie X., Hua L., Jiang W., Feng F., Feng G., Hua Z. Clinical application of a dendritic cell vaccine raised against heat-shocked glioblastoma. Cell Biochem. Biophys. 2012, 62(1):91-99.
15. Hoves S., Krause S., Schölmerich J., Fleck M. The JAM-assay: optimized conditions to determine death-receptor-mediated apoptosis. Methods 2003, 31:127-134.
16. Jewett A., Wang M.Y., Teruel A., Poupak Z., Bostanian Z., Park N.H. Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum. Immunol. 2003, 64(5):505-520.
17. Kim K., Fisher M.J., Xu S.Q., El-Deiry W.S. Molecular determinants of response to TRAIL in killing of normal and cancer cells. Clin. Cancer Res. 2000, 6(2):335-346.
18. Griffith T.S., Chin W.A., Jackson G.C., Lynch D.H., Kubin M.Z. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J. Immunol. 1998, 161(6):2833-2840.
19. Eggert A., Grotzer M.A., Zuzak T.J., Wiewrodt B.R., Ho R., Ikegaki N., et al. Resistance to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in neuroblastoma cells correlates with a loss of caspase-8 expression. Cancer Res. 2001, 61(4):1314-1319.
20. Jiang m{cyrillic}., Liu Z., Xiang Y., Ma H., Liu S., Liu Y., et al. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma. BMC Cancer 2011, 11:54.
21. Morton E., Blaho J. Herpes simplex virus blocks Fas-mediated apoptosis independent of viral activation of NF-kappaB in human epithelial HEp-2 cells. J. Interferon Cytokine Res. 2007, 27(5):365-376.
22. Louis D.N., Ohgaki H., Wiestler O.D., Cavenee W.K., et al. WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114(2):97-109.
23. Alyamkina E.A., Dolgova E.V., Likhacheva A.S., Rogachev V.A., Sebeleva T.E., Nikolin V.P., et al. Combined therapy with cyclophosphamide and DNA preparation inhibits the tumor growth in mice. Genet Vaccin. Ther. 2009, 7:12.
24. Phillips J.H., Lanier L.L. Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis. J. Exp. Med. 1987, 164:814-825.
25. Sarina B., Cortelezzi A., Cattaneo C., Pomati M., Silvestris I., Di Stefano M., et al. In vitro effects of IL-12 and IL-2 on NK cells, cytokine release and clonogenic activity in myelodysplastic syndromes (MDS). Leukemia 1997, 11:1726-1731.
26. Lu F., Fang J., Chen C.Q. TNF receptor-associated factor-2 binding site is involved in TNFR75-dependent enhancement of TNFR55-induced cell death. Cell Res. 2001, 11:217-222.
27. Lee N., Cheong H., Kim S., Kim S.E., Kim C.K., Lee K.T., et al. Ex vivo purging of leukemia cells using tumor-necrosis-factor-related apoptosis-inducing ligand in hematopoietic stem cell transplantation. Leukemia 2003, 17:1375-1383.
28. Rabinovich G.A., Gabrilovich D., Sotomayor E.M. Immunosuppressive strategies that are mediated by tumor cells. Annu. Rev. Immunol. 2007, 25(1):267-296.
29. Adema G.J. Dendritic cells from bench to bedside and back. Immunol. Lett. 2009, 122(2):128-130.
30. Gabrilovich D.I., Chen H.L., Girgis K.R., Cunningham H.T., Meny G.M., Nadaf S., et al. Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells. Nat. Med. 1996, 2:1096-1103.
31. Ratta M., Fagnoni F., Curti A., Vescovini R., Sansoni P., Oliviero B., et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 2002, 100:230-237.
32. Hoffmann T.K., Muller-Berghaus J., Ferris R.L., Johnson J.T., Storkus W.J., Whiteside T.L. Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. Clin. Cancer Res. 2002, 8:1787-1793.
33. Lissoni P., Vigore L., Ferranti R., Bukovec R., Meregalli S., Mandala M., et al. Circulating dendritic cells in early and advanced cancer patients: diminished percent in the metastatic disease. J. Biol. Regul. Homeost. Agents 1999, 13:216-219.
34. Almand B., Clark J.I., Nikitina E., van Beynen J., English N.R., Knight S.C., et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J. Immunol. 2001, 166:678-689.
35. Della Bella S., Gennaro M., Vaccari M., Ferraris C., Nicola S., Riva A., et al. Altered maturation of peripheral blood dendritic cells in patients with breast cancer. Br. J. Cancer 2003, 89:1463-1472.
36. Lakomy D., Janikashvili N., Fraszczak J., Trad M., Audia S., Samson M., et al. Cytotoxic dendritic cells generated from cancer patients. J. Immunol. 2011, 187:2775-2782.
37. Yang R., Xu D., Zhang A., Gruber A. Immature dendritic cells kill ovarian carcinoma cells by a FAS/FASL pathway, enabling them to sensitize tumor-specific CTLs. Int. J. Cancer 2001, 94(3):407-413.
38. Luettiq B., Decker T., Lohmann-Matthes M.L. Evidence for the existence of two forms of membrane tumor necrosis factor: an integral protein and a molecule attached to its receptor. J. Immunol. 1989, 143:4034-4038.
39. Lu G., Janjic B.M., Janjic J., Whiteside T.L., Storkus W.J., Vujanovic N.L. Innate direct anticancer effector function of human immature dendritic cells. II. Role of TNF, lymphotoxin-α1β2, Fas ligand, and TNF-related apoptosis-inducing ligand. J. Immunol. 2002, 168:1831-1839.
40. Knight M., Riffkin C., Muscat A., Ashley D., Hawkins C. Analysis of FasL and TRAIL induced apoptosis pathways in glioma cells. Oncogene 2001, 20:5789-5798.
41. Leplina O., Tikhonova M., Kozlov Yu., Stupak V., Ostanin A., Chernykh E. Characteristics of IFNα-indused dendritic cells in malignant brain gliomas patients. Bull. SB RAMS (Russ. J.) 2007, 124:27-33.
42. Akira S., Ishii K.J. Innate immune recognition of, and regulation by DNA. Trends Immunol. 2006, 27(11):525-532.
43. Barber G.N. STING-dependent signaling. Nat. Immunol. 2011, 12:929-930.
44. Coban C., Koyama S., Takeshita F., Akira S., Ishii K.J. Molecular and cellular mechanisms of DNA vaccines. Hum. Vaccin. 2008, 4:453-456.
45. Kawai T., Kumar H., Akira S. Pathogen recognition by the innate immune system. Int. Rev. Immunol. 2011, 30(1):16-34.
46. Takaoka A., Taniguchi T. Cytosolic DNA recognition for triggering innate immune responses. Adv. Drug Deliv. Rev. 2008, 60:847-857.
47. Trinchieri G., Matsumoto-Kobayashi M., Clark S.C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J. Exp. Med. 1984, 160:1147-1169.